BOLD — Boundless Bio Cashflow Statement
0.000.00%
Last trade - 00:00HealthcareSmall Cap
- $86.13m
- -$18.75m
Annual cashflow statement for Boundless Bio, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS/A | PROSPECTUS/A | PROSPECTUS/A |
| Standards: | USG | USG | USG |
| Status: | Final | Final | Final |
| Net Income/Starting Line | -25.2 | -45.9 | -49.4 |
| Depreciation | |||
| Non-Cash Items | 2.12 | 4.5 | 2.42 |
| Other Non-Cash Items | |||
| Changes in Working Capital | -0.837 | 0.866 | -0.799 |
| Change in Prepaid Expenses | |||
| Change in Accrued Expenses | |||
| Change in Payable / Accrued Expenses | |||
| Cash from Operating Activities | -23.2 | -39.6 | -46.9 |
| Capital Expenditures | -2.03 | -1.07 | -0.633 |
| Purchase of Fixed Assets | |||
| Other Investing Cash Flow Items | -57.3 | 17.2 | -37.6 |
| Sale/Maturity of Investment | |||
| Purchase of Investments | |||
| Cash from Investing Activities | -59.3 | 16.1 | -38.3 |
| Financing Cash Flow Items | — | 0 | -1.96 |
| Other Financing Cash Flow | |||
| Net Issuance / Retirement of Stock | |||
| Cash from Financing Activities | 106 | 0.126 | 97.9 |
| Beginning Cash Balance | |||
| Ending Cash Balance | |||
| Net Change in Cash | 23 | -23.3 | 12.8 |